SCHEMBL29964997

SCHEMBL29964997

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3cc(-c4ccc5c(c4)CCNC5=O)c(N)nc3F)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.40
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
ALK Q9UM73 1/20 0.40
ATR Q13535 1/20 0.39
PDK2 Q15119 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
MAPKAPK2 P49137 4/20 0.39
MAPK1 P28482 1/20 0.39
CCNT1 O60563 1/20 0.39
CDK4 P11802 1/20 0.39
CCNA2 P20248 1/20 0.39
CCND1 P24385 1/20 0.39
CDK2 P24941 1/20 0.39
CCND3 P30281 1/20 0.39
CDK7 P50613 1/20 0.39
CDK9 P50750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29964749 0.92 CDK4 (0.43) SMARCA2SMARCA4PBRM1ALKATR
SCHEMBL29964443 0.91 RET (0.39) RETSMARCA2SMARCA4PBRM1ALK
SCHEMBL31079257 0.91 SMARCA2 (0.40) RETSMARCA2SMARCA4PBRM1ALK
SCHEMBL29965043 0.90 RET (0.39) RETSMARCA2SMARCA4PBRM1ALK
SCHEMBL29964373 0.90 SMARCA2 (0.41) SMARCA2SMARCA4PBRM1MAPKAPK2MAPK1
SCHEMBL29964802 0.89 SMARCA2 (0.40) SMARCA2SMARCA4PBRM1MAPKAPK2MAPK1
SCHEMBL29964262 0.88 MAPK1 (0.45) RETMAPK1GSK3BGPR119DDB1
SCHEMBL29964158 0.87 SMARCA2 (0.38) SMARCA2SMARCA4PBRM1MAPKAPK2MAPK1
SCHEMBL29964714 0.87 JAK2 (0.39) MAPKAPK2MAPK1CDK4CCND1CCND3
SCHEMBL31079181 0.87 CDK9 (0.42) ATRCCNT1CDK7CDK9NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 RET 889/4885SMARCA2 3906/4885SMARCA4 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.